Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Pediatric Subjects at Risk for a Venous or Arterial Thrombotic Disorder
Phase of Trial: Phase I
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Apixaban (Primary)
- Indications Thromboembolism
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 12 Apr 2016 Planned number of patients changed from 40 to 44.
- 15 Oct 2015 Planned End Date changed from 1 Aug 2016 to 1 Oct 2017 as reported by ClinicalTrials.gov.
- 15 Oct 2015 Planned primary completion date changed from 1 Aug 2016 to 1 Oct 2017 as reported by ClinicalTrials.gov